Compare Qurate Retail Inc Series A (QVCAQ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qurate Retail Inc Series A vs Viatris Inc — how do they compare? Qurate Retail Inc Series A trades at $0.04 (market cap $653.75K), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 31357.6× Qurate Retail Inc Series A's market cap, and Viatris Inc pays a 2.73% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| QVCAQ | VTRS | |
|---|---|---|
Market Cap | $653.75K | $20.50B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.03 | $17.59 |
52-Week Low | $0.05 | $8.74 |
Enterprise Value | $4.73B | $32.71B |
Dividend Yield | — | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
